• Founding General Partner of IngleWood Ventures in 1999
• Founding VC and Board Member of CardioNet (NASDAQ-BEAT) & Cylene Pharmaceuticals and led IngleWood into Conforma Therapeutics first round
• Currently on Boards of LineaGen, Inc. and Satiogen Pharmaceuticals and Board Observer at Elevation Pharmaceuticals, Traversa Therapeutics, Medipacs, Biomatrica, and Exagen Diagnostics.
• Extensive Network in the Southwest
• San Diego-based investment professional since 1978
• Has known the Sanderling team for many years
• Service on portfolio company comp, audit and executive search committees
• Knows CEOs from experience publishing Golden State BioBusiness News for 13 years

-Dan Wood is General Partner of Mesa Verde Venture Partners, an early-stage bioscience venture capital fund focused on the Southwestern United States.  Prior to forming Mesa Verde in late 2006, Mr. Wood had been co-founding General Partner of IngleWood Ventures of San Diego in 1999.  IngleWood has performed 14 bioscience company investments, primarily in very early-stage companies in San Diego County.  Until 2007, Mr. Wood had served on the Board of Directors of CardioNet (NASDAQ-BEAT) for seven years and Cylene Pharmaceuticals for six years.  Dan led the first institutional rounds of financing for these companies.  He was also a Board Observer at Conforma Therapeutics (acquired by Biogen-Idec) and Digirad (NASDAQ-DRAD).  Prior to forming IngleWood in 1999, he had served as president of the Sorrento Corporation, a Registered Investment Advisory firm he formed in 1985 in San Diego.  Mr. Wood is a Tufts University graduate and holds an MBA in Finance from the University of Connecticut and the Chartered Financial Analyst designation.